Dose standardization of botulinum toxin.

[1]  M. Muenter,et al.  Early cinematographic cases of postencephalitic parkinsonism and other movement disorders , 1998, Movement disorders : official journal of the Movement Disorder Society.

[2]  C. Sampaio,et al.  DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1 , 1997, Movement disorders : official journal of the Movement Disorder Society.

[3]  K. Wohlfarth,et al.  Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences , 1997, Experimental Neurology.

[4]  M. Merello,et al.  Sleep benefit in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.

[5]  A. Braun,et al.  Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)O PET study. , 1997, Brain : a journal of neurology.

[6]  K. Wohlfarth,et al.  Botulinum A toxins: units versus units , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  G. Plazzi,et al.  Propriospinal myoclonus upon relaxation and drowsiness: A cause of severe insomnia , 1997, Movement disorders : official journal of the Movement Disorder Society.

[8]  R. Benecke,et al.  The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A , 1997 .

[9]  R. Sloop,et al.  Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans If It Is Refrozen or Refrigerated for 2 Weeks Before Use , 1997, Neurology.

[10]  S. Sangla,et al.  Dose standardisation of botulinum toxin. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[11]  L. Pearce,et al.  The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. , 1995, Toxicon : official journal of the International Society on Toxinology.

[12]  L. Pearce,et al.  Measurement of botulinum toxin activity: evaluation of the lethality assay. , 1994, Toxicology and applied pharmacology.

[13]  P. Hambleton,et al.  Dose standardisation of botulinum toxin , 1994, The Lancet.

[14]  M. Goodnough,et al.  Stabilization of botulinum toxin type A during lyophilization , 1992, Applied and environmental microbiology.

[15]  E. Schantz,et al.  Dose standardisation of botulinum toxin , 1990, The Lancet.

[16]  M. Hallett,et al.  DOSE STANDARDISATION OF BOTULINUM TOXIN , 1989, The Lancet.

[17]  J. Nutt,et al.  Diurnal responsiveness to apomorphine , 1987, Neurology.

[18]  B. Whaler,et al.  Influence of nerve‐ending activity and of drugs on the rate of paralysis of rat diaphragm preparation by Cl. botulinum type A toxin , 1962, The Journal of physiology.

[19]  E. Rüther,et al.  Relationship between cerebral blood flow velocities and cerebral electrical activity in sleep. , 1994, Sleep.

[20]  W. Koller,et al.  Historical review: Abnormal movements associated with epidemic encephalitis lethargica , 1987, Movement disorders : official journal of the Movement Disorder Society.

[21]  J. D. Parkes,et al.  Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .

[22]  D. Kautter,et al.  Standardized Assay for Clostridium botulinum Toxins , 1978 .